Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture.
Adenosine Monophosphate
/ analogs & derivatives
Alanine
/ analogs & derivatives
Antiviral Agents
/ pharmacology
COVID-19
/ virology
Cell Culture Techniques
Cell Line
Coronavirus Papain-Like Proteases
/ antagonists & inhibitors
Drug Repositioning
/ methods
Drug Synergism
Hepacivirus
/ drug effects
Hepatitis C
/ drug therapy
Humans
Molecular Docking Simulation
Molecular Dynamics Simulation
Protease Inhibitors
/ pharmacology
SARS-CoV-2
/ drug effects
Virus Replication
/ drug effects
COVID-19 Drug Treatment
COVID-19
HCV protease inhibitors
SARS-CoV-2 3CL/M(pro) protease
SARS-CoV-2 PL protease
SARS-CoV-2 virus replication
antivirals
molecular docking
remdesivir
synergism
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
18 05 2021
18 05 2021
Historique:
received:
16
11
2020
revised:
18
03
2021
accepted:
23
04
2021
pubmed:
14
5
2021
medline:
29
5
2021
entrez:
13
5
2021
Statut:
ppublish
Résumé
Effective control of COVID-19 requires antivirals directed against SARS-CoV-2. We assessed 10 hepatitis C virus (HCV) protease-inhibitor drugs as potential SARS-CoV-2 antivirals. There is a striking structural similarity of the substrate binding clefts of SARS-CoV-2 main protease (M
Identifiants
pubmed: 33984267
pii: S2211-1247(21)00472-1
doi: 10.1016/j.celrep.2021.109133
pmc: PMC8075848
pii:
doi:
Substances chimiques
Antiviral Agents
0
Protease Inhibitors
0
remdesivir
3QKI37EEHE
Adenosine Monophosphate
415SHH325A
Coronavirus Papain-Like Proteases
EC 3.4.22.2
papain-like protease, SARS-CoV-2
EC 3.4.22.2
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109133Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM120574
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM141818
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI135972
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI142733
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests A provisional patent application related to these studies has been filed. G.T.M. is a founder of Nexomics Biosciences, Inc. The A.G.-S. laboratory has received research support from Pfizer, Senhwa Biosciences, 7Hills Pharma, Avimex, Blade Therapeutics, Dynavax, ImmunityBio, Nanocomposix, Pharmamar, and Kenall Manufacturing, and A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Pagoda, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Accurius, Pfizer, and Esperovax. These relationships have no conflict of interest with respect to this study.
Références
Cell Res. 2020 Aug;30(8):678-692
pubmed: 32541865
J Virol. 2004 Dec;78(24):13600-12
pubmed: 15564471
Nat Protoc. 2016 May;11(5):905-19
pubmed: 27077332
IUCrJ. 2020 Sep 21;7(Pt 6):
pubmed: 33063790
Nucleic Acids Res. 1989 Jun 26;17(12):4847-61
pubmed: 2526320
Crit Rev Biochem Mol Biol. 2019 Feb;54(1):11-26
pubmed: 30821513
Arch Biochem Biophys. 2007 Oct 1;466(1):8-14
pubmed: 17692280
J Med Chem. 2020 May 14;63(9):4562-4578
pubmed: 32045235
mBio. 2017 Nov 21;8(6):
pubmed: 29162711
Nucleic Acids Res. 2020 Jul 2;48(W1):W488-W493
pubmed: 32246720
J Mol Biol. 1993 Sep 5;233(1):123-38
pubmed: 8377180
Structure. 2020 Dec 1;28(12):1313-1320.e3
pubmed: 33152262
Spectrochim Acta A Mol Biomol Spectrosc. 2018 Jun 5;198:297-303
pubmed: 29558729
Nat Commun. 2020 Sep 4;11(1):4417
pubmed: 32887884
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
Curr Protoc Microbiol. 2020 Sep;58(1):e108
pubmed: 32585083
J Mol Graph Model. 1999 Feb;17(1):57-61
pubmed: 10660911
ACS Cent Sci. 2021 May 26;7(5):792-802
pubmed: 34075346
Nat Commun. 2021 Feb 2;12(1):743
pubmed: 33531496
ACS Cent Sci. 2020 May 27;6(5):672-683
pubmed: 32483554
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
Science. 2020 Sep 11;369(6509):1395-1398
pubmed: 32763915
Nucleic Acids Res. 1999 Jan 1;27(1):244-7
pubmed: 9847191
Nat Commun. 2016 Sep 02;7:12754
pubmed: 27587337
Trends Microbiol. 2020 Dec;28(12):1022-1033
pubmed: 32536523
Sci Transl Med. 2020 Apr 29;12(541):
pubmed: 32253226
J Virol. 2002 Apr;76(8):3697-708
pubmed: 11907209
mBio. 2013 Aug 13;4(4):
pubmed: 23943763
Curr Top Med Chem. 2009;9(9):755-70
pubmed: 19754393
J Med Chem. 2007 May 17;50(10):2310-8
pubmed: 17444623
Cell Rep. 2020 Jun 16;31(11):107774
pubmed: 32531208
Science. 2020 Apr 24;368(6489):409-412
pubmed: 32198291
EMBO J. 2002 Jul 1;21(13):3213-24
pubmed: 12093723
J Mol Biol. 2017 Jun 2;429(11):1661-1683
pubmed: 28438633
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16119-24
pubmed: 18852458
Curr Opin Biotechnol. 2009 Aug;20(4):429-36
pubmed: 19733475
Antimicrob Agents Chemother. 2020 Aug 20;64(9):
pubmed: 32669265
Cell Rep. 2020 Jun 16;31(11):107772
pubmed: 32553163
Nature. 2020 Jun;582(7811):289-293
pubmed: 32272481
Sci Adv. 2020 Dec 9;6(50):
pubmed: 33158912
Virus Res. 2008 Apr;133(1):63-73
pubmed: 17397958
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
Nucleic Acids Res. 2015 Jul 1;43(W1):W443-7
pubmed: 25873628
PLoS Biol. 2020 Jun 8;18(6):e3000715
pubmed: 32511245
Mol Cell. 2017 Nov 2;68(3):581-590.e5
pubmed: 29100055
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508